Symbols

CTMX

CytomX Therapeutics·NASDAQ

--(--)

CTMX fundamentals

CTMX Q4 2025 Earnings

CytomX Therapeutics (CTMX) released its earnings on Mar 16, 2026: revenue was 661.00K (YoY -98.26%), missed estimates; EPS was -0.33 (YoY -250.00%), missed estimates.

Revenue / YoY

661.00K

-98.26%

EPS / YoY

-0.33

-250.00%

Report date

Mar 16, 2026

CTMX Earnings Call Summary for Q4,2025

Breakthrough Efficacy: Varseta-M achieves 32% ORR at 10 mg/kg in late-line CRC, with median PFS of 7.1 months.
Safety Advancement: Grade 3 diarrhea reduced to 10% with dual prophylaxis and AIBW dosing.
Strategic Expansion: Targeting third-line CRC approval by 2027, with plans to expand into earlier lines and EpCAM-positive cancers.
Innovative Dosing: Adjusted ideal body weight strategy enhances efficacy predictability and tolerability.

Earnings

EPS

Revenue

Revenue & Expenses

CTMX has released its 2025 Q4 earnings report, with revenue of 663.00K, reflecting a YoY change of -98.26%, and net profit of -26.51M, showing a YoY change of -240.44%. The Sankey diagram below clearly presents CTMX's revenue sources and cost distribution.

Key Indicators

CytomX Therapeutics (CTMX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

CytomX Therapeutics (CTMX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

CytomX Therapeutics (CTMX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

CytomX Therapeutics (CTMX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown